Phagos

Get email alerts

New customer deployments for Phagos, straight to your inbox. No account needed.

Phagos has 2 source-linked AI deployments documented in AIUseCaseHub, across 2 industries and 1 country.

Use Cases

Industries

Countries

Hyperscaler mix

See whether Phagos's cases are powered by Microsoft, AWS, GCP, or multiple providers.

How Phagos builds AIBuild, Buy & Compose — what they mean
Build — Custom, pro-code engineering — bespoke pipelines and SDKs (e.g. Bedrock, Vertex AI).
Buy — An off-the-shelf assistant or copilot, adopted as the main solution.
Compose — Low-code / no-code assembly (e.g. Copilot Studio, Power Platform, n8n).
Mixed — A combination of more than one of the above.

Build / Buy / Compose across this company's documented cases

100%

BuildBuyComposeMixed

2 of 2 cases classified (100%) · Compare all use-case types

Use case portfolio

Use case types at Phagos

Drug discovery leads with 1 of 2 documented cases; 2 distinct types appear across the visible portfolio.

Ranked by documented casesShare of visible cases

Browse type directory

Technology snapshot

What Phagos uses across visible cases

Fine-Tuned Models appears in 2 of 2 indexed cases; 5 named technologies are mentioned, led by Amazon EC2.

Capability mix

Fine-Tuned Models100%

Technologies mentioned

Amazon EC22 Amazon RDS2 Amazon S32 Amazon SageMaker1 Amazon SageMaker AI1

All Use Cases (2)

Phagos uses Amazon SageMaker AI to create customized sustainable antibiotic alternatives

Phagos applies generative AI to match bacteriophages with target bacteria for personalized phage therapy.The company built AI models on AWS to simulate millions of phage-bacteria interactions and accelerate treatment discovery.

PharmaJul 2026

Fine-tuning

Phagos Uses Amazon SageMaker Generative AI to Revolutionize Bacterial Infection Treatment

Phagos, a Paris-based biotech startup, is pioneering AI-powered phage therapy to combat antibiotic-resistant bacterial infections using generative AI models on Amazon SageMaker to match bacteriophages to specific bacteria.The challenge addressed is the inefficiency and slowness of traditional antibiotic development amid rising antibiotic resistance causing millions of deaths annually.Phagos developed predictive AI models trained on genomic data using Amazon SageMaker, and utilizes Amazon EC2 for computation, Amazon S3 and RDS for scalable and secure data storage, enabling rapid phage-bacteria matching.The AI platform reduced treatment development time from over 10 years to about two months, achieved 99.5% time savings in phage screening, and allowed deployment in animal farming with plans for human use by 2030.

HealthcareApr 2026

Fine-tuning

Community

Comments

No published comments yet.

Ask the analyst

A question about Phagos the page doesn't answer? I read every one — the good ones get answered here.